维普期刊资源整合服务平台（V6.5）

22篇 您的检索式：作者名="David Cella"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated with Radioembolization, Compared with Chemoembolization显示文摘	Riad Salem Margaret Gilbertsen Zeeshan Butt Khairuddin Memon Michael Vouche Ryan Hickey Talia Baker Michael M. Abecassis Rohi Atassi Ahsun Riaz David Cella James L. Burns Daniel Ganger Al B. Benson Mary F. Mulcahy Laura Kulik Robert Lewandowski	2013	Clinical Gastroenterology and Hepatology2013，，：	2
2	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial显示文摘	Brian I Rini Bernard Escudier Piotr Tomczak Andrey Kaprin Cezary Szczylik Thomas E Hutson M Dror Michaelson Vera A Gorbunova Martin E Gore Igor G Rusakov Sylvie Negrier Yen-Chuan Ou Daniel Castellano Ho Yeong Lim Hirotsugu Uemura Jamal Tarazi David Cella	2011	The Lancet . 2011 (9807)2011，，9807：	2
3	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial显示文摘	Brian I Rini Bernard Escudier Piotr Tomczak Andrey Kaprin Cezary Szczylik Thomas E Hutson M Dror Michaelson Vera A Gorbunova Martin E Gore Igor G Rusakov Sylvie Negrier Yen-Chuan Ou Daniel Castellano Ho Yeong Lim Hirotsugu Uemura Jamal Tarazi David Cella	2011	The Lancet2011，，9807：	2
4	Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale显示文摘BACKGROUND Although oxaliplatin is widely established as a standard treatment in colorectal cancer(CRC),oxaliplatin-induced neuropathy has emerged as a prominent doselimiting side effect associated with quality of life decrements.Ongoing monitoring and management of neuropathy is important for CRC patient quality of life and adherence to treatment.Therefore,a validated self-reported measure of neuropathy would aid in the management and assessment of oxaliplatininduced neuropathy in clinical practice and research.We sought to evaluate the content validity of the 13-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale(FACT/GOGNtx)for CRC patients receiving oxaliplatin.AIM To understand the neuropathy experiences of CRC patients and assess content validity of the FACT/GOG-Ntx.METHODS Semi-structured concept elicitation and cognitive debriefing interviews were conducted with 31 CRC patients experiencing peripheral neuropathy from current or previous oxaliplatin treatment.Interview data were analyzed using a constant comparative approach,and data were mapped to the FACT/GOG-Ntx to assess content validity.RESULTS Mean age of the sample was 54(range 34-82).The sample was primarily Caucasian(84%)and consisted of nearly equal numbers of men and women.Participants described 28 unique neuropathy symptoms;hand tingling(experienced by 87%of respondents);feet tingling(81%);hand numbness(68%);and feet numbness(84%)were most frequently mentioned.Neuropathy symptoms occurring on the feet were most often identified as most bothersome by participants.Eleven of the 13 FACT/GOG-Ntx items exhibited moderate to strong evidence of content validity.Two items related to trouble hearing and ringing in the ears had weak support;however,these items represent severe neuropathy and could be useful for a patient reported outcome measure.CONCLUSION The FACT/GOG-Ntx represents the key neuropathy experiences of CRC patients treated with oxaliplatin.	Karen Kaiser Madison Lyleroehr Sara Shaunfield Leilani Lacson Maria Corona Sheetal Kircher Malin Nittve David Cella	2020	World Journal of Gastrointestinal Oncology2020，12，2：	2
5	Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study显示文摘	Karen Kaiser Rajiv Mallick Zeeshan Butt Mary F. Mulcahy Al B. Benson David Cella	2014	Supportive Care in Cancer2014，，4：	1
6	Advances in quality of life measurements in oncology patients显示文摘	David Cella Chih-Hung Chang Jin-Shei Lai Kimberly Webster	2002	Seminars in Oncology2002，，3：	1
7	Methods and problems in measuring quality of life显示文摘	David F. Cella	1995	Supportive Care in Cancer1995，，1：	1
8	Patient-Related Barriers to Fatigue Communication显示文摘	Steven D Passik Kenneth L Kirsh Kathleen Donaghy Elizabeth Holtsclaw Dale Theobald David Cella William Breitbart	2002	Journal of Pain and Symptom Management2002，，5：	1
9	Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire显示文摘	David Cella Sally E. Jensen Kimberly Webster Du Hongyan Jin-Shei Lai Steven Rosen Martin S. Tallman Susan Yount	2012	Value in Health2012，，8：	1
10	Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: A Gynecologic Oncology Group study显示文摘	Richard P. McQuellon Howard T. Thaler David Cella David H. Moore	2005	Gynecologic Oncology2005，，2：	1
11	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B显示文摘	Lesley J Fallowfield Samantha K Leaity Anthony Howell Sarah Benson David Cella	1999	Breast Cancer Research and Treatment1999，，2：	1
12	Nutritional Recommendations for the Management of Sarcopenia显示文摘	John E. Morley Josep M. Argiles William J. Evans Shalender Bhasin David Cella Nicolaas E.P. Deutz Wolfram Doehner Ken C.H. Fearon Luigi Ferrucci Marc K. Hellerstein Kamyar Kalantar-Zadeh Herbert Lochs Neil MacDonald Kathleen Mulligan Maurizio Muscaritoli	2010	Journal of the American Medical Directors Association2010，，：	1
13	Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument显示文摘	Wendy L. Ward Elizabeth A. Hahn Fei Mo Lesbia Hernandez David S. Tulsky David Cella	1999	Quality of Life Research1999，，3：	1
14	Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument显示文摘	Peg Esper Fei Mo Gerald Chodak Michael Sinner David Cella Kenneth J. Pienta	1997	Urology1997，，6：	1
15	Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp)显示文摘	Amy H. Peterman Ph.D. George Fitchett D. Min. Marianne J. Brady Ph.D. Lesbia Hernandez Pharm.D. M.P.H. David Cella Ph.D	2002	Annals of Behavioral Medicine2002，，1：	1
16	Normative data for functional assessment of cancer therapy:General scale and its use for the interpretation of quality of life scores in cancer survivors显示文摘	Bernhard Holzner Georg Kemmler David Cella	2001	Acta Oncologica2001，43，2：	1
17	A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment显示文摘	Carolyn Miller Reilly Deborah Watkins Bruner Sandra A. Mitchell Lori M. Minasian Ethan Basch Amylou C. Dueck David Cella Bryce B. Reeve	2013	Supportive Care in Cancer2013，，6：	1
18	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial显示文摘	Robert J. Motzer Dmitry Nosov Timothy Eisen Igor Bondarenko Vladimir Lesovoy Oleg Lipatov Piotr Tomczak Oleksiy Lyulko Anna Alyasova Mihai Harza Mikhail Kogan Boris Y. Alekseev Cora N. Sternberg Cezary Szczylik David Cella Cristina Ivanescu Andrew Krivosh	2013	Journal of Clinical Oncology2013，，：	1
19	Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)显示文摘	Kathleen J. Yost Susan E. Yount David T. Eton Cheryl Silberman Anne Broughton-Heyes David Cella	2005	Breast Cancer Research and Treatment2005，，3：	1
20	Advances in quality of life measurements in oncology patients显示文摘	David Cella Chang Chih-hong J Lai in-shei	2002	Seminars in Oncol2002，29，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示